Monoclonal antibodies in the treatment of multiple sclerosis. (Record no. 19314671)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 01252 a2200361 4500 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20250515194706.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 201002s 0 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1875-533X |
024 7# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.2174/092986709789909585 |
Source of number or code | doi |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | NLM |
Language of cataloging | eng |
Transcribing agency | NLM |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Di Pauli, F |
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Date of production, publication, distribution, manufacture, or copyright notice | 20100224 |
245 00 - TITLE STATEMENT | |
Title | Monoclonal antibodies in the treatment of multiple sclerosis. |
Medium | [electronic resource] |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Name of publisher, distributor, etc. | Current medicinal chemistry |
Date of publication, distribution, etc. | 2009 |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 4858-68 p. |
Other physical details | digital |
500 ## - GENERAL NOTE | |
General note | Publication Type: Journal Article; Review |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Alemtuzumab |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Antibodies, Monoclonal |
General subdivision | adverse effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Antibodies, Monoclonal, Humanized |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Antibodies, Monoclonal, Murine-Derived |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Antibodies, Neoplasm |
General subdivision | therapeutic use |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Clinical Trials as Topic |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Daclizumab |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Humans |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Immunoglobulin G |
General subdivision | therapeutic use |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Multiple Sclerosis |
General subdivision | drug therapy |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Natalizumab |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Rituximab |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Berger, T |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Reindl, M |
773 0# - HOST ITEM ENTRY | |
Title | Current medicinal chemistry |
Related parts | vol. 16 |
-- | no. 36 |
-- | p. 4858-68 |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://doi.org/10.2174/092986709789909585">https://doi.org/10.2174/092986709789909585</a> |
Public note | Available from publisher's website |
No items available.